News Related to Cordex Biologics

Related coverage linked through entity extraction aliases.

Zemcelpro (dorocubicel) Receives NUB Status 1 in Germany and Expands Asia Access

Jul 30, 2026

Zemcelpro (dorocubicel) has achieved NUB Status 1 in Germany, enabling hospitals to seek temporary reimbursement, while Cordex Biologics expanded access to Asia and Argentina through a distribution deal with FarmaMondo. The cell therapy holds conditional EU authorization for certain blood cancers.

Zemcelpro Receives NUB Status 1 in Germany, Enabling Hospital Reimbursement Applications

Feb 16, 2026

ExCellThera's cell therapy Zemcelpro (dorocubicel) has been granted NUB Status 1 in Germany, allowing hospitals to apply for temporary supplementary reimbursement. 220 German hospitals have expressed interest in offering the therapy in 2026.